Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

New Psychometric Strategies for the Evaluation of Affective, Cognitive, and Psychosocial Functioning in Unipolar versus Bipolar Depression: Impact of Drug Treatment

Author(s): Claudia Savia Guerrera*, Giuseppe Alessio Platania, Simone Varrasi, Simona De Vivo, Concetta Pirrone, Venera Francesca Vezzosi, Fabio Tascedda, Filippo Drago, Santo Di Nuovo, Johanna M.C. Blom, Sabrina Castellano and Filippo Caraci*

Volume 23, Issue 2, 2024

Published on: 14 April, 2023

Page: [262 - 270] Pages: 9

DOI: 10.2174/1568007X04666230313091253

Price: $65

Abstract

Background: Different studies have been conducted to understand how patients with unipolar and bipolar depression differ in terms of cognitive and affective symptoms as well as in psychosocial function. Furthermore, the impact of antidepressants, second-generation antipsychotics, and mood stabilizers on these dimensions needs to be characterized, as well as the best psychometric approach to measure changes after pharmacological treatment.

Objectives: This study aims to analyze the impact of psychotropic drugs on cognitive, affective, and psychosocial functioning in MDD and BD patients; to test the sensitivity of psychometric tools for measuring those changes; also, to understand how psychosocial abilities are associated with affective and cognitive dimensions in patients with MDD and BD.

Methods: A total of 22 patients with MDD and 21 patients with BD in the depressive phase were recruited. Several psychometric tests were administered to assess affective, cognitive, and psychosocial symptoms before and after 12 weeks of drug treatment (T0 and T1) with different psychotropic drugs including second-generation antidepressants, second-generation antipsychotics and mood stabilizers (lamotrigine).

Results: MDD patients showed significant improvement in MoCA, Delayed Recall of Rey’s 15 Words and HDRS, while a significant worsening was detected on Digit Span Backwards and on FAST scores. Instead, patients with BD showed significant improvements in the MoCA as the MDD patients, but only a trend of improvement (non-statistically significant) on the BDI-II. A positive correlation was detected in both groups between FAST and HDRS and BDI-II scores, especially in BD patients.

Conclusion: Our results demonstrate that drug treatment with psychotropic drugs can improve cognitive and affective symptoms, but not all psychometric tools may be equally sensitive to detect those changes in MDD vs. BD patients. Moreover, we found that affective and cognitive dimensions can be considered as different psychopathological dimensions both in unipolar and bipolar depression.

« Previous
Graphical Abstract

[1]
Hirschfeld RM. Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord 2014; 169 (Suppl. 1): S12-6.
[http://dx.doi.org/10.1016/S0165-0327(14)70004-7] [PMID: 25533909]
[2]
Solé B, Jiménez E, Torrent C, et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol 2017; 20(8): 670-80.
[http://dx.doi.org/10.1093/ijnp/pyx032] [PMID: 28498954]
[3]
MacQueen GM, Memedovich KA. Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options. Psychiatry Clin Neurosci 2017; 71(1): 18-27.
[http://dx.doi.org/10.1111/pcn.12463] [PMID: 27685435]
[4]
Tolentino JC, Schmidt SL. DSM-5 Criteria and depression severity: Implications for clinical practice. Front Psychiatry 2018; 9: 450.
[http://dx.doi.org/10.3389/fpsyt.2018.00450] [PMID: 30333763]
[5]
Gruber S, Rathgeber K, Bräunig P, Gauggel S. Stability and course of neuropsychological deficits in manic and depressed bipolar patients compared to patients with Major Depression. J Affect Disord 2007; 104(1-3): 61-71.
[http://dx.doi.org/10.1016/j.jad.2007.02.011] [PMID: 17360041]
[6]
Ahern E, Semkovska M. Cognitive functioning in the first-episode of major depressive disorder: A systematic review and meta-analysis. Neuropsychology 2017; 31(1): 52-72.
[http://dx.doi.org/10.1037/neu0000319] [PMID: 27732039]
[7]
Wang Y, Gao Y, Tang S, et al. Large-scale network dysfunction in the acute state compared to the remitted state of bipolar disorder: A meta-analysis of resting-state functional connectivity. EBioMedicine 2020; 54: 102742.
[http://dx.doi.org/10.1016/j.ebiom.2020.102742] [PMID: 32259712]
[8]
Fava M. Pharmacological strategies for targeting residual symptoms in depression. Trivedi MH, Strakowski SM, editors Depression Oxford University Press. 2019; p. 257-67. (Primer On Series).
[9]
Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: Recent advances and novel treatments. Neuropsychiatr Dis Treat 2019; 15: 1249-58.
[http://dx.doi.org/10.2147/NDT.S199746] [PMID: 31190831]
[10]
Bourne C, Aydemir Ö, Balanzá-Martínez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatr Scand 2013; 128(3): 149-62.
[http://dx.doi.org/10.1111/acps.12133] [PMID: 23617548]
[11]
Bortolato B, Miskowiak KW, Köhler CA, Vieta E, Carvalho AF. Cognitive dysfunction in bipolar disorder and schizophrenia: A systematic review of meta-analyses. Neuropsychiatr Dis Treat 2015; 11(12): 3111-25.
[PMID: 26719696]
[12]
Castellano S, Ventimiglia A, Salomone S, et al. Selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors improve cognitive function in partial responders depressed patients: results from a prospective observational cohort study. CNS Neurol Disord Drug Targets 2016; 15(10): 1290-8.
[http://dx.doi.org/10.2174/1871527315666161003170312] [PMID: 27712575]
[13]
Castellano S, Torrent C, Petralia MC, et al. Clinical and neurocognitive predictors of functional outcome in depressed patients with partial response to treatment: one year follow-up study. Neuropsychiatr Dis Treat 2020; 16: 589-95.
[http://dx.doi.org/10.2147/NDT.S224754] [PMID: 32184600]
[14]
Platania G, Varrasi S, Castellano S, et al. Biological and neuropsychological markers of cognitive dysfunction in unipolar vs. bipolar Depression: What evidence do we have. Life Span Disabil 2020; 23: 239-81.
[15]
Daniel BD, Montali A, Gerra ML, et al. Cognitive impairment and its associations with the path of illness in affective disorders: A comparison between patients with bipolar and unipolar depression in remission. J Psychiatr Pract 2013; 19(4): 275-87.
[http://dx.doi.org/10.1097/01.pra.0000432597.79019.e2] [PMID: 23852102]
[16]
Cullen B, Nicholl BI, Mackay DF, et al. Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants. Eur Psychiatry 2015; 30(8): 950-8.
[http://dx.doi.org/10.1016/j.eurpsy.2015.08.006] [PMID: 26647871]
[17]
Bo Q, Dong F, Li X, et al. Comparison of cognitive performance in bipolar disorder, major depressive disorder, unaffected first‐degree relatives, and healthy controls. Psychiatry Clin Neurosci 2019; 73(2): 70-6.
[http://dx.doi.org/10.1111/pcn.12797] [PMID: 30393945]
[18]
Xu G, Lin K, Rao D, et al. Neuropsychological performance in bipolar I, bipolar II and unipolar depression patients: A longitudinal, naturalistic study. J Affect Disord 2012; 136(3): 328-39.
[http://dx.doi.org/10.1016/j.jad.2011.11.029] [PMID: 22169253]
[19]
Cotrena C, Branco LD, Shansis FM, Fonseca RP. Executive function impairments in depression and bipolar disorder: Association with functional impairment and quality of life. J Affect Disord 2016; 190: 744-53.
[http://dx.doi.org/10.1016/j.jad.2015.11.007] [PMID: 26606718]
[20]
Solé B, Jiménez E, Martinez-Aran A, Vieta E. Cognition as a target in major depression: New developments. Eur Neuropsychopharmacol 2015; 25(2): 231-47.
[http://dx.doi.org/10.1016/j.euroneuro.2014.12.004] [PMID: 25640673]
[21]
Godard J, Baruch P, Grondin S, Lafleur MF. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: A 12-month prospective study. Psychiatry Res 2012; 196(1): 145-53.
[http://dx.doi.org/10.1016/j.psychres.2011.09.013] [PMID: 22370154]
[22]
Wang SM, Han C, Lee SJ, et al. Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J 2016; 52(3): 159-72.
[http://dx.doi.org/10.4068/cmj.2016.52.3.159] [PMID: 27689026]
[23]
Zajecka JM. Residual symptoms and relapse: Mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry 2013; 74 (Suppl. 2): 9-13.
[http://dx.doi.org/10.4088/JCP.12084su1c.02] [PMID: 24191972]
[24]
Pillarella J, Higashi A, Alexander GC, Conti R. Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatr Serv 2012; 63(1): 83-6.
[http://dx.doi.org/10.1176/appi.ps.201100092] [PMID: 22227765]
[25]
Rhee TG, Olfson M, Wilkinson ST. Changes in pharmacotherapeutic approaches in the treatment of bipolar disorder by primary care physicians. Gen Hosp Psychiatry 2020; 67: 141-3.
[http://dx.doi.org/10.1016/j.genhosppsych.2020.03.002] [PMID: 32184005]
[26]
Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry 2020; 177(8): 706-15.
[http://dx.doi.org/10.1176/appi.ajp.2020.19091000] [PMID: 32312111]
[27]
Guerrera CS, Furneri G, Grasso M, et al. Antidepressant drugs and physical activity: a possible synergism in the treatment of major depression. Front Psychol 2020; 11: 857.
[http://dx.doi.org/10.3389/fpsyg.2020.00857] [PMID: 32435223]
[28]
Dias VV, Balanzá-Martinez V, Soeiro-de-Souza MG, et al. Pharmacological approaches in bipolar disorders and the impact on cognition: A critical overview. Acta Psychiatr Scand 2012; 126(5): 315-31.
[http://dx.doi.org/10.1111/j.1600-0447.2012.01910.x] [PMID: 22881296]
[29]
Pavuluri MN, Passarotti AM, Mohammed T, Carbray JA, Sweeney JA. Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder. Bipolar Disord 2010; 12(2): 213-20.
[http://dx.doi.org/10.1111/j.1399-5618.2010.00792.x] [PMID: 20402714]
[30]
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders: DSM-5. (5th ed.). Washington, D.C: American Psychiatric Association 2013; p. 947.
[31]
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23(1): 56-62.
[http://dx.doi.org/10.1136/jnnp.23.1.56] [PMID: 14399272]
[32]
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278-96.
[http://dx.doi.org/10.1111/j.2044-8260.1967.tb00530.x] [PMID: 6080235]
[33]
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4(6): 561-71.
[http://dx.doi.org/10.1001/archpsyc.1961.01710120031004] [PMID: 13688369]
[34]
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res 1975; 12(3): 189-98.
[http://dx.doi.org/10.1016/0022-3956(75)90026-6] [PMID: 1202204]
[35]
Cohen J. Statistical power analysis for the behavioral sciences. (2nd ed.), Hillsdale, NJ: Erlbaum 1988.
[36]
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695-9.
[http://dx.doi.org/10.1111/j.1532-5415.2005.53221.x] [PMID: 15817019]
[37]
Pinto TCC, Machado L, Bulgacov TM, et al. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) in the elderly. Int Psychogeriatr 2019; 31(4): 491-504.
[http://dx.doi.org/10.1017/S1041610218001370] [PMID: 30426911]
[38]
Ciesielska N, Sokołowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kędziora-Kornatowska K. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in Mild Cognitive Impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol 2016; 50(5): 1039-52.
[http://dx.doi.org/10.12740/PP/45368] [PMID: 27992895]
[39]
Rey A. L’examen clinique en psychologie. The clinical examination in psychology. Oxford, England: Presses Universitaries De France; 1958. 222 p. (L’examen clinique en psychologie.).
[40]
Cha DS, Carmona NE, Subramaniapillai M, et al. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. J Affect Disord 2017; 222: 14-20.
[http://dx.doi.org/10.1016/j.jad.2017.06.036] [PMID: 28667888]
[41]
Ji Y, Li W, Liu B, et al. Clinical characteristics of cognitive deficits in major depressive disorder: A 6-month prospective study. Arch Clin Psychiatry 2020; 47(4): 101-5.
[http://dx.doi.org/10.1590/0101-60830000000241]
[42]
Han H, Hou Y, Yao S, et al. The relationship between cognitive dysfunction through THINC-integrated tool (THINC-it) and psychosocial function in chinese patients with major depressive disorder. Front Psychiatry 2021; 12: 763603.
[http://dx.doi.org/10.3389/fpsyt.2021.763603] [PMID: 34887790]
[43]
Snyder A, Gruber-Baldini AL, Rainer von Coelln F, et al. Comparison of mini-mental state examination and montreal cognitive assessment ratings across levels of Parkinson’s Disease severity. J Parkinsons Dis 2021; 11(4): 1995-2003.
[http://dx.doi.org/10.3233/JPD-212705] [PMID: 34366371]
[44]
Suda S, Muraga K, Ishiwata A, et al. Early cognitive assessment following acute stroke: feasibility and comparison between mini-mental state examination and montreal cognitive assessment. J Stroke Cerebrovasc Dis 2020; 29(4): 104688.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2020.104688] [PMID: 32063455]
[45]
Nazem S, Siderowf AD, Duda JE, et al. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc 2009; 57(2): 304-8.
[http://dx.doi.org/10.1111/j.1532-5415.2008.02096.x] [PMID: 19170786]
[46]
Carneiro AM, Fernandes F, Moreno RA. Hamilton depression rating scale and montgomery–asberg depression rating scale in depressed and bipolar I patients: Psychometric properties in a Brazilian sample. Health Qual Life Outcomes 2015; 13(1): 42.
[http://dx.doi.org/10.1186/s12955-015-0235-3] [PMID: 25889742]
[47]
John Rush A, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 1986; 18(1): 65-87.
[http://dx.doi.org/10.1016/0165-1781(86)90060-0] [PMID: 3737788]
[48]
Hunt M, Auriemma J, Cashaw ACA. Self-report bias and underreporting of depression on the BDI-II. J Pers Assess 2003; 80(1): 26-30.
[http://dx.doi.org/10.1207/S15327752JPA8001_10] [PMID: 12584064]
[49]
Pan Z, Park C, Brietzke E, et al. Cognitive impairment in major depressive disorder. CNS Spectr 2019; 24(1): 22-9.
[http://dx.doi.org/10.1017/S1092852918001207] [PMID: 30468135]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy